Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16261384 | 0.82 | POLB (0.46) | KDM4EALDH1A1PAX8ACHEMEN1 | |
| SCHEMBL15867017 | 0.82 | POLB (0.46) | KDM4EALDH1A1PAX8ACHEMEN1 | |
| SCHEMBL945538 | 0.81 | — | — | |
| SCHEMBL22870065 | 0.78 | TP53 (0.34) | KDM4EALDH1A1MAPTPAX8JAK1 | |
| SCHEMBL22870070 | 0.78 | TP53 (0.34) | KDM4EALDH1A1MAPTPAX8JAK1 | |
| SCHEMBL24634254 | 0.76 | ACHE (0.39) | KDM4EALDH1A1MAPTPAX8ACHE | |
| SCHEMBL16478638 | 0.76 | ACHE (0.39) | KDM4EALDH1A1MAPTPAX8ACHE | |
| SCHEMBL16472376 | 0.76 | ACHE (0.39) | KDM4EALDH1A1MAPTPAX8ACHE | |
| SCHEMBL20620971 | 0.75 | PAX8 (0.33) | ALDH1A1PAX8JAK1TP53 | |
| SCHEMBL20760334 | 0.75 | TSHR (0.34) | PAX8JAK1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | IDO1, IDO2, TDO2 | KDM4E 771/4885ALDH1A1 819/4885MAPT 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.